International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors

  title={International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors},
  author={Liliane Michalik and Johan Auwerx and Joel P. Berger and V. Krishna K. Chatterjee and Christopher K. Glass and Frank J. Gonzalez and Paul Andr{\'e} Grimaldi and Takashi Kadowaki and Mitchell A. Lazar and Stephen O’Rahilly and Colin Neil Alexander Palmer and Jorge Plutzky and Janardan K. Reddy and Bruce M Spiegelman and Bart Staels and Walter Wahli},
  journal={Pharmacological Reviews},
  pages={726 - 741}
The three peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors of the nuclear hormone receptor superfamily. They share a high degree of structural homology with all members of the superfamily, particularly in the DNA-binding domain and ligand- and cofactor-binding domain. Many cellular and systemic roles have been attributed to these receptors, reaching far beyond the stimulation of peroxisome proliferation in rodents after which they were initially… 

Figures from this paper

In Vivo Actions of Peroxisome Proliferator–Activated Receptors

In man, the primary effect of PPARα is to reduce plasma triglyceride concentration; effects on plasma free fatty acid (FFA) concentration/FFA oxidation, muscle/liver fat content, and muscle/hepatic insulin sensitivity have not been demonstrated with current PPARβ/δ agonists such as fenofibrate and gemfibrozil.

Expression and Function of PPARs in Placenta

Peroxisome proliferator-activated receptors (PPAR) are members of the superfamily of nuclear hormone receptors involved in embryonic development and differentiation of several tissues including

Peroxisome proliferator-activated receptors for hypertension World Journal of Cardiology

The range of PPAR γ agonist therapeutic actions will result in novel approaches to lifestyle and other diseases, and the combination ofPPARs with reagents or with other cardiovascular drugs, such as diuretics and angiotensin Ⅱ receptor blockers, should be studied.

Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels.

These functions suggest that PPARs serve as physiological sensors in different stress situations and remain valuable targets for innovative therapies.

Role of peroxisome proliferator-activated receptors alpha and gamma in gastric ulcer: An overview of experimental evidences.

  • L. Saha
  • Biology
    World journal of gastrointestinal pharmacology and therapeutics
  • 2015
In all the studies, both the PPARγ activators showed protection against the gastric ulcer and also accelerate the ulcer healing in gastrics ulcer model in rats, Therefore, PPARα and PParγ may be a target for gastric Ulcer therapy.

Peroxisome proliferator-activated receptor beta/delta goes vascular.

Roles for PPARβ/δ in adipose tissue formation, metabolism, wound healing, brain development, placental function, colorectal carcinogenesis, and skeletal muscle function are implicated.


The current review illustrates the effect of various PPAR agonists on obesity with respect to lipid and lipoprotein metabolism, glucose homeostasis, weight gain associated with insulin resistance in type 2 diabetic patients, cell proliferation, fibrogenesis and differentiation.



A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation.

X-ray crystallography revealed that GW0072 occupied the ligand-binding pocket by using different epitopes than the known PPAR agonists and did not interact with the activation function 2 helix, establishing an approach to the design of PPAR ligands with modified biological activities.

The mechanisms of action of PPARs.

The current state of knowledge regarding the molecular mechanisms of PPAR action and the involvement of the PPARs in the etiology and treatment of several chronic diseases is presented.

Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?

It is now established that the species difference between rodents and humans in response to peroxisome proliferators is due in part to PPAR alpha, and future research directions that should be taken to delineate the mechanisms underlying PPARalpha agonist-induced hepatocarcinogenesis are identified.

Peroxisome proliferator-activated receptor-α and liver cancer: where do we stand?

It is now established that the species difference between rodents and humans in response to peroxisome proliferators is due in part to PPAR α, and future research directions that should be taken to delineate the mechanisms underlying PPARα agonist-induced hepatocarcinogenesis are identified.

Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.

The role of PPARs in the vasculature is focused on and the present understanding of their effects on atherogenesis and its cardiovascular complications is summarized.

Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat.

This work presents the expression patterns of the PPAR subtypes in the adult rat, determined by in situ hybridization using specific probes for PPAR-alpha, -beta and -gamma, and by immunohistochemistry using a polyclonal antibody that recognizes the three rat PPar subtypes.

The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation

It is shown that PPAR-γ is markedly upregulated in activated macrophages and inhibits the expression of the inducible nitric oxide synthase, gelatinase B and scavenger receptor A genes in response to 15d-PGJ2 and synthetic PPar-γ ligands, suggesting that PPARS and locally produced prostaglandin D2 metabolites are involved in the regulation of inflammatory responses.

Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids (*)

Results indicate that PPARs are differentially activated by naturally occurring eicosanoids and related molecules.

Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology.

The clinical consequences of PPARgamma polymorphisms in humans, as well as several studies in mice using general or tissue-specific knockout techniques, are reviewed, allowing us to hypothesize a general mechanism of PPargamma action and speculate on future trends in the use of PP ARgamma as a target in the treatment of type II diabetes.

Ligand type-specific Interactions of Peroxisome Proliferator-activated Receptor γ with Transcriptional Coactivators*

It is suggested that ligand binding may alterPPARγ structure in a ligand type-specific way, resulting in distinct PPARγ-coactivator interactions.